John Moller, Novotech CEO

Novotech's lat­est ac­qui­si­tions grow its US pres­ence and plant a Eu­ro­pean foothold

Over the past few years, the CRO Novotech has ce­ment­ed its po­si­tion in the Asia-Pa­cif­ic re­gion, but its lat­est move will see it plant­i­ng its flag on two dif­fer­ent con­ti­nents.

On Mon­day, Novotech an­nounced it has ac­quired two CROs: the Col­orado-based CBR In­ter­na­tion­al and the Poland-based east­HORN.

CBR is a con­sul­tan­cy com­pa­ny fo­cused on guid­ing phar­ma com­pa­nies through FDA re­quire­ments and of­fers ser­vices that in­clude reg­u­la­to­ry strat­e­gy, FDA rep­re­sen­ta­tion and sci­en­tif­ic af­fairs to sup­port cGMP re­quire­ments, among oth­ers. The ac­qui­si­tion will now al­low Novotech to add US and glob­al reg­u­la­to­ry, qual­i­ty and de­vel­op­ment ser­vices to its ar­se­nal. This in­cludes as­sist­ing with sub­mis­sions such as IND, BLA, fast track and or­phan drug ap­pli­ca­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA